Immunization, Hib3 in Europe & Central Asia (IDA & IBRD countries)
Europe & Central Asia (IDA & IBRD countries): Immunization, Hib3 was 93.4% in 2024. ◆ Volatile
Immunization, Hib3 in Europe & Central Asia (IDA & IBRD countries), 1992–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
In 2024, immunization, hib3 in Europe & Central Asia (IDA & IBRD countries) stood at 93.4%.
Compared with earlier readings it is down 0.7% on the previous year and up 50.3% over ten years.
Over the whole period, immunization, hib3 in Europe & Central Asia (IDA & IBRD countries) peaked at 94.1% in 2023 and was at its lowest, 0.0%, in 1992.
Europe & Central Asia (IDA & IBRD countries) ranks 3rd of 43 groups on this measure, in the top 10%.
The series is highly variable year to year, so single readings are best treated with caution.
Immunization, Hib3 in Europe & Central Asia (IDA & IBRD countries), year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 1992 | 0.0% | — |
| 1993 | 0.0% | — |
| 1994 | 0.0% | — |
| 1995 | 0.0% | — |
| 1996 | 0.0% | — |
| 1997 | 0.0% | — |
| 1998 | 0.0% | — |
| 1999 | 0.0% | — |
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 0.6% | — |
| 2003 | 0.7% | +14.9% |
| 2004 | 1.1% | +48.2% |
| 2005 | 2.4% | +131.4% |
| 2006 | 4.7% | +94.5% |
| 2007 | 28.6% | +502.3% |
| 2008 | 40.3% | +41.1% |
| 2009 | 53.8% | +33.3% |
| 2010 | 57.7% | +7.3% |
| 2011 | 61.4% | +6.4% |
| 2012 | 67.5% | +9.9% |
| 2013 | 66.7% | -1.1% |
| 2014 | 62.1% | -6.9% |
| 2015 | 62.8% | +1.1% |
| 2016 | 63.1% | +0.5% |
| 2017 | 62.8% | -0.5% |
| 2018 | 66.5% | +5.9% |
| 2019 | 69.6% | +4.7% |
| 2020 | 69.1% | -0.8% |
| 2021 | 69.8% | +1.1% |
| 2022 | 92.0% | +31.8% |
| 2023 | 94.1% | +2.2% |
| 2024 | 93.4% | -0.7% |
Biggest year-on-year movements
Years where Immunization, Hib3 in Europe & Central Asia (IDA & IBRD countries) changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2007 | +502.3% | 4.7% | 28.6% |
| 2005 | +131.4% | 1.1% | 2.4% |
| 2006 | +94.5% | 2.4% | 4.7% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | 8 |
| 2000s | 13.2% | 0.0% | 53.8% | 10 |
| 2010s | 64.0% | 57.7% | 69.6% | 10 |
| 2020s | 83.7% | 69.1% | 94.1% | 5 |
Countries ranked near Europe & Central Asia (IDA & IBRD countries)
- 1 Antigua and Barbuda 99.0% compare
- 1 Brunei 99.0% compare
- 1 Costa Rica 99.0% compare
- 1 Cuba 99.0% compare
- 1 Greece 99.0% compare
- 1 Hungary 99.0% compare
- 1 Jamaica 99.0% compare
- 1 North Korea 99.0% compare
- 1 Kuwait 99.0% compare
- 1 Luxembourg 99.0% compare
- 1 Maldives 99.0% compare
- 1 Monaco 99.0% compare
- 1 Oman 99.0% compare
- 1 Palau 99.0% compare
- 1 Portugal 99.0% compare
- 1 Saint Lucia 99.0% compare
- 1 Saint Vincent and the Grenadines 99.0% compare
- 1 Tonga 99.0% compare
- 1 Turkey 99.0% compare
More health data for Europe & Central Asia (IDA & IBRD countries)
- Population ages 30-34, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, female, annual growth rate 1.34 % change on previous year (2025)
- Population ages 35-39, male, per capita 0.0402 units per person (2025)
- Population ages 35-39, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, male, annual growth rate -0.0639 % change on previous year (2025)
- Population ages 35-39, female, per capita 0.0397 units per person (2025)
- Population ages 35-39, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, female, annual growth rate -0.1882 % change on previous year (2025)
- Population ages 30-34, male, per capita 0.035 units per person (2025)
- Population ages 25-29, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is immunization, hib3 in Europe & Central Asia (IDA & IBRD countries)?
- Immunization, hib3 in Europe & Central Asia (IDA & IBRD countries) was 93.4% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in Europe & Central Asia (IDA & IBRD countries)?
- The highest recorded value was 94.1% in 2023.
- What is the lowest immunization, hib3 recorded in Europe & Central Asia (IDA & IBRD countries)?
- The lowest recorded value was 0.0% in 1992.
- How does Europe & Central Asia (IDA & IBRD countries) rank for immunization, hib3?
- Europe & Central Asia (IDA & IBRD countries) ranks 3rd out of 43 groups with data for 2024.
- Is immunization, hib3 rising or falling in Europe & Central Asia (IDA & IBRD countries)?
- Over the last ten years it is up 50.3%. The long-run trend across the full record is volatile.
- Where does this Europe & Central Asia (IDA & IBRD countries) data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 33 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.